Corporate Profile for Boehringer Mannheim Corp., dated Sept. 20, 1996.--(BUSINESS WIRE)--The following Corporate Profile is available for inclusion in your files. News releases for this client are distributed by Business Wire and also become part of the leading databases and information services See Information Systems. . These include Dow Jones News/Retrieval, Bloomberg Financial Markets, Reuter Company Newsyear, Reuter Business Briefing, DataTimes, Nexis, Dialog, NewsNet, America OnLine, CompuServe, Delphi, Individual's HeadsUp and First!, Desktop Data's NewsEdge, UMI UMI University Microfilms International UMI United States Minor Outlying Islands (ISO Country code) UMI University of Miami UMI Universal Management Infrastructure (IBM) Data Courier, NewsBank, Information Access Company, Prodigy, Comtex, and many others. -0- Published Date: Sept. 20, 1996 Company Name: Boehringer Mannheim Corp., Therapeutics Division
Address: 101 Orchard Ridge Drive
Gaithersburg, MD 20878
Main Telephone Number: 800/628-2672 Senior VP U.S. Therapeutics: John Melville Manager, Marketing Communications Contact: Kevin Kramer Business number: 301/216-3733 e-mail address: kevin_kramer@bmpc.corange.com URL: www.boehringer-mannheim.com Industry: Pharmaceutical, Biotechnology-0- Company description: Boehringer Mannheim Corp., Therapeutics Division (BMCT BMCT Branch Movement Control Team BMCT Bwindi Mgahinga Conservation Trust BMCT British Motorcycle Charitable Trust BMCT Before Morning Civil Twilight BMCT Bit Map Conversion Table BMCT Brief Management Counselling & Training ) was established in 1984 in Rockville, Md. BMCT is a division of Boehringer Mannheim Corp. (BMC (BMC Software, Inc., Houston, TX, www.bmc.com) A leading supplier of software that supports and improves the availability, performance, and recovery of applications in complex computing environments. ) located in Indianapolis. With divisions in Diagnostics, Therapeutics, and Biochemicals, BMC is the U.S. member of the Boehringer Mannheim Group of Mannheim, Germany. Boehringer Mannheim has operating divisions in 26 countries, and products available in 150 countries. After building a drug development group, BMCT sales and marketing launched its first commercial product, ISMO ISMO Isosorbide-5-Mononitrate ISMO Information Systems Management Office ISMO Information Systems Missions Order ISMO Implicit Space Mapping Optimization ISMO Information Systems Management Order ISMO Intensive Support Mutual Obligation (job search) for chronic stable angina chronic stable angina Cardiology The most common form of angina, characterized by chest discomfort due to myocardial ischemia, and unaccompanied by myocardial necrosis; the cause of pain is uncertain, possibly substances released during transient ischemia–eg, , followed in 1994 by DEMADEX, a loop diuretic loop diuretic n. A class of diuretic agents that act by inhibiting reabsorption of sodium and chloride. loop diuretic for the treatment of edema edema (ĭdē`mə), abnormal accumulation of fluid in the body tissues or in the body cavities causing swelling or distention of the affected parts. associated with congestive heart failure congestive heart failure, inability of the heart to expel sufficient blood to keep pace with the metabolic demands of the body. In the healthy individual the heart can tolerate large increases of workload for a considerable length of time. . Along with DEMADEX and ISMO, BMCT currently markets CARDIAC T Rapid Assay and MICRAL in partnership with BMC Diagnostics. BMCT moved to Gaithersburg in 1994 and currently employs over 400 in the United States, including a field sales force of 265 representatives. BMCT focuses on research, development and marketing of products in the following therapeutic areas: cardiovascular, renal, oncology, metabolism (bone and diabetes), antivirals/antiinfectives, and gene medicine. The parent company of BMCT was one of the first to develop synthetic pharmaceuticals, formulate early intravenous drugs for cardiac patients, introduce oral anti-diabetic agents, and pioneer biotechnology drug development. Boehringer Mannheim has built a heritage of quality worldwide with over 140 years of experience. Today, Boehringer Mannheim's principal biotechnology facility in Penzburg, Germany is fully equipped to handle all levels of biotechnological development with more than 1,500 biotechnology products and approximately 200 recombinant products. Key Statistics Industry: Biotechnology Segment: Human Therapeutics Ownership: Subsidiary Employees: 400 Revenue: (US $ mil.) Sales: 3.27 billion - 1995 Privately owned CONTACT: Boehringer Mannheim 
We bought the Refloux S from our Singapore Pharmacy & right now there is some technical problem, We check with the Pharmacy and they told us that this product is life time guarantee but there is no Singapore office for this product. Appreciate if your kind advice.
Low Elin elinlsc@yahoo.com |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion